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Hyperglycaemia is associated with increased mortality and morbidity in neonatal intensive care. STAR-GRYPHON is a model-based glycaemic control protocol, which uses insulin sensitivity to tailor insulin treatments to patients and changing patient condition. It is implemented as a standard of care in a neonatal intensive care unit in Christchurch, New Zealand.   
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1.	Introduction
High blood glucose (BG), hyperglycaemia, in the neonatal intensive care unit (NICU) affects 30-70% of extremely premature infants (gestational age ≤ 27 weeks), and is associated with increased risk of infection, ventilator dependence, hospital length of stay and mortality. Increasingly, evidence suggests that controlling the blood sugar levels to a normal range can prevent and reduce the extent of morbidities, thus improving patient outcomes and reducing the costs of care.  
STAR-GRYPHON (Stochastic TARgeted Glycaemic Regulation sYstem to Prevent Hyper-and hypO-glycaemia in Neonates) is a model-based protocol for dosing insulin in very premature infants. It is currently being used as a standard of care in Christchurch (CCH), New Zealand (NZ). It is also being implemented in Miskolc, Hungary, and as part of a randomized trial in Auckland (NZ). Presented here are clinical results from its use in CCH.
2. Model based control
Mathematical models of glucose-insulin physiology are used. Inter-patient variability is managed directly by identifying insulin sensitivity from data available at the bedside. Prediction of future sensitivity values using cohort based statistical modelling allows likely BG outcomes to be forecast for a given treatment. Typically, treatments are selected such that the risk of BG<4.4 mmol/L is 5%, maximising likelihood of  outcomes in the target range of 4.0-8.0 mmol/L.
2.3 Implementation
STAR-GRYPHON is implemented on a tablet computer interface, designed in conjunction with clinical staff. Starting criteria for insulin is two consecutive BG>10 mmol/L in 4-6 hrs. 
3. Results
STAR-GRYPHON achieves more BG within the clinically targeted range than retrospective data, with much less hypoglycaemia, which can also be dangerous. 




GA (weeks)	27 [25-27]	26 [25-27]
Weight (g)	845 [800-900]	925 [750-1030]
PNA (days)	N/A	3 [1.5-3.5]
Clinical interventions
Meas. intrvl. (hr)	3.2 [2.6 - 3.9]	4.0 [3.9-4.1]
Insulin (U/kg/hr)	0.03 [0.02-0.06]	0.05 [0.04 -0.07]
Performance
Median BG	7.8 [6.6- 9.1]	6.9 [6.2-7.8]





#  episodes with BG <2.6 	1 (4)	0 (0)
All BG units are mmol/L. Data given as median [IQR]. GA is gestational age, PNA is post-natal age.
4. Summary
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